Chemotherapy has been studied extensively in advanced prostatě cancer, especially in the hormone-refractory prostatě cancer (HRCP) setting. Docetaxel is currently among the most active agents for managing HRCP. In phase II trials, single-agent docetaxel induced PSA response (> 50 % decline of PSA, range 41%-64%) in 42% of treated men. In these trials, weekly administration of docetaxel appeared to be better tolerated than the 3-week dosing regimen, producing less neutropenia. Patients, methods and results: Thirty-two patients were treated with docetaxel 40 mg/m2, repeated weekly for 6 weeks of an 8-week cycle. Seventeen of 32 patients achieved > 50 % decline of PSA, eight of 32 patients achieved > 25 % decline of PSA. Time to progression of PSA levels was 22 weeks and medián survival of 20 patients was 16.8 months. Toxicity was moderate, with following grade 3/4 toxicities: nail toxicity, alopecia.

        Key words: hormone-refractory prostatě cancer (HRCP), PSA, weekly docetaxel